Vitenskapelig artikkel

• Dennis Karlheinz Völkl; Malte Mensching-Buhr; Thomas Sterr et al. (2025). HIDE: Hierarchical cell-type deconvolution. (ekstern lenke)
• Martin Pilskog; Leif Bostad; Reidunn Jetne Edelmann et al. (2018). Tumour cell expression of interleukin 6 receptor a is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. (ekstern lenke)
• E Vuhahula; Oddbjørn Straume; Lars A. Akslen (2000). Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. (ekstern lenke)
• Cornelia Schuster; Lars A. Akslen; Oddbjørn Straume (2016). Expression of Heat Shock Protein 27 in melanoma metastases is associated with overall response to bevacizumab monotherapy: Analyses of predictive markers in a clinical phase II study. (ekstern lenke)
• Gry Sandvik Haaland; Ragnhild Sørum Falk; Oddbjørn Straume et al. (2017). Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. (ekstern lenke)
• Martin Pilskog; Gry Hilde Nilsen; Christian Beisland et al. (2019). Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. (ekstern lenke)
• Ingeborg Bachmann; Oddbjørn Straume; Hanne Eknes Puntervoll et al. (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. (ekstern lenke)
• Oddbjørn Straume; Lars A. Akslen (2005). Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. (ekstern lenke)
• Yanina Jeanne Leona Jansen; Elisa A. Lisette Rozeman; Robert Mason et al. (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. (ekstern lenke)
• Lars A. Akslen; Oddbjørn Straume; Stephanie Geisler et al. (2011). Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. (ekstern lenke)
• Hanna Dillekås; Romano Demicheli; Ilaria Ardoino et al. (2016). The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases. (ekstern lenke)
• Oddbjørn Straume; Helga Salvesen; Lars A. Akslen (1999). Angiogenesis is prognostically important in vertical growth phase melanomas. (ekstern lenke)
• Lars A. Akslen; Sabrina Angelini; Oddbjørn Straume et al. (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. (ekstern lenke)
• Oddbjørn Straume; Lars A. Akslen (1999). Loss of nuclear expression of p16 protein correlates with increased tumor cell proliferation and poor patient outcome in patients with vertical growth phase melanoma. (Abstract no. P-487). (ekstern lenke)
• Oddbjørn Straume; Takeshi Shimamura; Michael J.G. Lampa et al. (2012). Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. (ekstern lenke)
• Hanna Elisabet Dillekås; Monica Transeth; Martin Pilskog et al. (2014). Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases. (ekstern lenke)
• Charalampos Tzoulis; Thomas Schwarzlmüller; Ivar Otto Gjerde et al. (2015). Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. (ekstern lenke)
• Ingeborg Margrethe Bachmann; Ole Johan Halvorsen; Karin Collett et al. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. (ekstern lenke)
• Romano Demicheli; Hanna Dillekås; Oddbjørn Straume et al. (2019). Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal. (ekstern lenke)
• Mikyung Kelly Seo; Oddbjørn Straume; Lars A. Akslen et al. (2020). HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?. (ekstern lenke)
• Martin Pilskog; Christian Beisland; Lars A. Akslen et al. (2017). Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. (ekstern lenke)
• George N. Naumov; Judah Folkman; Oddbjørn Straume (2009). Tumor dormancy due to failure of angiogenesis: role of the microenvironment. (ekstern lenke)
• George N. Naumov; Monique B. Nilsson; Tina Cascone et al. (2009). Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. (ekstern lenke)
• Michael S. Rogers; Katherine Novak; David Zurakowski et al. (2014). Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. (ekstern lenke)
• Jarle Arnes; Ingunn Marie Stefansson; Oddbjørn Straume et al. (2012). Vascular proliferation is a prognostic factor in breast cancer. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2012). Tumor necrosis is a prognostic factor in thick cutaneous melanoma. (ekstern lenke)
• Dag Hoem; Oddbjørn Straume; Heike Immervoll et al. (2013). Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma. (ekstern lenke)
• Oddbjørn Straume; L. Sviland; L.A. Akslen (2000). Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2014). Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. (ekstern lenke)
• Elin Aamdal; Kari Dolven Jacobsen; Oddbjørn Straume et al. (2021). Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. (ekstern lenke)
• Kristi Krüger; Laxmi Silwal-Pandit; Elisabeth Wik et al. (2021). Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2010). Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. (ekstern lenke)
• Agnete Engelsen; Katarzyna Wnuk-Lipinska; Sébastien Bougnaud et al. (2020). AXL is a driver of stemness in normal mammary gland and breast cancer. (ekstern lenke)
• Cornelia Schuster; Lars Andreas Akslen; Oddbjørn Straume (2023). β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma. (ekstern lenke)
• Rakel Brendsdal Forthun; Randi Hovland; Cornelia Schuster et al. (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. (ekstern lenke)
• Cornelia Schuster; Lars A. Akslen; Tomasz Stokowy et al. (2019). Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. (ekstern lenke)
• Ingeborg M. Bachmann; Rita Grude Ladstein; Oddbjørn Straume et al. (2008). Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. (ekstern lenke)
• GN Naumov; J Folkman; Oddbjørn Straume (2008). Tumor dormancy due to failure of angiogenesis: role of the microenvironment. (ekstern lenke)
• Elin Aamdal; Eva Skovlund; Kari Dolven Jacobsen et al. (2022). Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment. (ekstern lenke)
• George N. Naumov; Elise Bender; David Zurakowski et al. (2006). A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. (ekstern lenke)
• Oddbjørn Straume; L.A. Akslen (2001). Expression of vascular endothelial growth factor, its receptors (FLT-1. KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. (ekstern lenke)
• Oddbjørn Straume; Lars A. Akslen (2004). Lymphatic vessel density and prognosis in cutaneous melanoma. (ekstern lenke)
• Lars A. Akslen; Hanne Eknes Puntervoll; Ingeborg M. Bachmann et al. (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2012). Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma. (ekstern lenke)
• R Kumar; J Smeds; P Berggren et al. (2001). A single nucleotide polymorphism in the 3' untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. (ekstern lenke)
• Hanna Dillekås; Michael S. Rogers; Oddbjørn Straume (2019). Are 90% of deaths from cancer caused by metastases?. (ekstern lenke)
• Cornelia Schuster; Hans Petter Eikesdal; Hanne Eknes Puntervoll et al. (2012). Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. (ekstern lenke)

Kasusrapport

• Jørgen Gitlesen Krohn; Liv Iren Hansen Vinnem; Ragnhild Wivestad Jansson et al. (2025). Fundus hypopigmentation and choroidal thinning associated with tebentafusp therapy: report of a case and literature review. (ekstern lenke)

Fremhevet artikkel i media

• Marianne Guren; Eirik Malinen; Sigbjørn Smeland et al. (2024). Kreftbehandling: Nå er det mulig å tilby mer skånsom stråleterapi for kreftpasienter. (ekstern lenke)

Konferanseposter

• Hanna Dillekås; Camilla Kristoffersen; Svein Arthur Jensen et al. (2019). Perioperative factors and complications after delayed reconstruction in breast cancer patients in relation to oncologic outcome. (ekstern lenke)
• Martin Pilskog; Christian Beisland; Oddbjørn Straume (2015). C-reactive protein as a predictive marker of response to sunitinib treatment in metastatic clear cell renal cell carcinoma. (ekstern lenke)
• Romano Demicheli; Hanna Dillekås; Oddbjørn Straume et al. (2018). Surgeries reveal details of metastasis development. (ekstern lenke)
• Martin Pilskog; Oddbjørn Straume (2017). Predictive value of IL6Rα in patients with metastatic clear cell renal cell carcinoma treated with sunitinib. (ekstern lenke)
• Oddbjørn Straume; Takeshi Shimamura; Anne Margrete Øyan et al. (2009). Suppression of heat shock Protein 27 induces long-term dormancy in human breast cancer. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Ragnhild Reehorst Lereim; Claire Dunn; Elin Aamdal et al. (2024). Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival. (ekstern lenke)
• George N. Naumov; Judah Folkman; Oddbjørn Straume et al. (2008). Tumor-vascular interactions and tumor dormancy. (ekstern lenke)
• Tor-Christian Aase Johannessen; Marek Wagner; Oddbjørn Straume et al. (2013). Tumor vasculature: the Achilles' heel of cancer?. (ekstern lenke)
• Hanna Dillekås; Oddbjørn Straume (2019). The link between wound healing and escape from tumor dormancy. (ekstern lenke)
• Jürgen Geisler; Ingeborg M. Bachmann; Marta Sølvi Nyakas et al. (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. (ekstern lenke)

Leserbrev

• Oddbjørn Straume; Jann Bergheim; Peter Ernst (2006). Bevacizumab therapy for POEMS syndrome. (ekstern lenke)
• Hanne Sommerfelt; Lene Frøyen Sandvik; Ingeborg Margrethe Bachmann et al. (2022). Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. (ekstern lenke)

Konferanseforedrag

• Oddbjørn Straume (2013). Angiogenesis as a treatment target in melanoma. (ekstern lenke)
• Oddbjørn Straume (2013). Nye behandlingsformer for inoperabelt metastatisk malignt melanom. (ekstern lenke)
• Hanna Dillekås; Romano Demicheli; Ilaria Ardoino et al. (2016). Hva betyr sekundær rekonstruksjon for senere tilbakefall?. (ekstern lenke)
• Hanna Dillekås; Romano Demicheli; Ilaria Ardoino et al. (2016). Recurrence of breast cancer in relation to delayed reconstruction. (ekstern lenke)
• Anders Molven; H Immervold; K Kugarajh et al. (2003). Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas. (ekstern lenke)

Forelesning

• Oddbjørn Straume (2013). Angiogenesis as a treatment target in metastatic melanoma. (ekstern lenke)

Doktorgradsavhandling

• Cornelia Schuster; Oddbjørn Straume (2016). Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab. (ekstern lenke)
• Oddbjørn Straume (2002). Biological and prognostic markers in cutaneous malignant melanoma. (ekstern lenke)
• Hanna Dillekås; Svein Arthur Hønsi Jensen; Oddbjørn Straume (2020). Importance of physical trauma on recurrence of breast cancer. (ekstern lenke)

Konferanseabstrakt

• Cornelia Schuster; Gro Gausdal; Bjørn Tore Gjertsen et al. (2018). Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. (ekstern lenke)

Vitenskapelig bokkapittel

• Oddbjørn Straume; Cornelia Schuster (2017). The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. (ekstern lenke)
• Hanna Dillekås; Cornelia Schuster; Kjersti Davidsen et al. (2022). The Role of the Microenvironment in Tumor Promoting Stress Responses. (ekstern lenke)

Lærebok

• Oddbjørn Straume; Jürgen Geisler; Hans Petter Gullestad et al. (2016). MEDIKAMENTELL KREFTBEHANDLING - Cytostatikaboken 8. utgave, Kapittel 34 - Malignt melanom. (ekstern lenke)

Kapittel i fagbok

• Thoralf Christoffersen; Åslaug Helland; Olav Engebråten et al. (2016). Signalhemmere. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.